# Family Care Hos (NSE: FAMILYCARE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/FAMILYCARE · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹16 Cr, it ranks 3701st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.

Its return on equity was −328.0% in FY25. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹0 Cr (+150.0% year on year) and net profit −₹0 Cr, on a standalone basis. Promoters held 17.47% of the company as of 30 Jun 2026; 65.47% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹16 Cr |
| ROE | −328.0% (FY25) |
| ROCE | 219.1% (FY25) |
| Debt to equity | 0.25 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹0 Cr | +150.0% | −₹0 Cr | — | −₹0.08 |
| Q4 FY26 | ₹0 Cr | +200.0% | −₹2 Cr | −344.4% | −₹0.45 |
| Q3 FY26 | ₹0 Cr | +100.0% | −₹1 Cr | — | −₹0.18 |
| Q2 FY26 | ₹0 Cr | −98.2% | −₹5 Cr | — | −₹0.85 |
| Q1 FY26 | ₹0 Cr | −99.5% | −₹1 Cr | −404.3% | −₹0.13 |
| Q4 FY25 | ₹0 Cr | −99.5% | ₹1 Cr | −88.5% | ₹0.18 |
| Q3 FY25 | ₹0 Cr | −99.7% | −₹2 Cr | −287.5% | −₹0.39 |
| Q2 FY25 | ₹4 Cr | −68.8% | −₹43 Cr | −3,534.1% | −₹8.01 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹8 Cr | −₹44 Cr |
| FY24 | ₹40 Cr | ₹13 Cr |
| FY23 | ₹47 Cr | ₹5 Cr |
| FY22 | ₹42 Cr | ₹5 Cr |
| FY21 | ₹35 Cr | ₹4 Cr |
| FY20 | ₹13 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 17.47%
- Domestic institutions: 0.09%
- Non-institutions: 82.44%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Vanta Bioscienc](https://app.pivotnow.in/stock/VANTABIO) | — | ₹17 Cr | — | — |
| [Venmax Drugs](https://app.pivotnow.in/stock/VENMAX) | — | ₹17 Cr | — | — |
| [Zenith Health](https://app.pivotnow.in/stock/ZENITHHE) | — | ₹17 Cr | — | — |
| [Colinz Labs](https://app.pivotnow.in/stock/COLINZ) | — | ₹15 Cr | — | — |
| [Starsource Mult](https://app.pivotnow.in/stock/STARSOURCE) | — | ₹14 Cr | — | — |
| [Norris Medicine](https://app.pivotnow.in/stock/NORRIS) | — | ₹14 Cr | — | — |

## Questions and answers

### What is the market cap of Family Care Hos?

Family Care Hos' market capitalisation is ₹16 Cr (₹16 Cr) at the 22 Oct 2026 close, ranking 3701st among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Family Care Hos?

Return on equity was −328.0% in FY25 and return on capital employed was 219.1% in FY25 (standalone figures).

### Is Family Care Hos a debt-free company?

No. Family Care Hos' debt-to-equity ratio was 0.25 in FY25, with total debt of ₹0 Cr.

### What were Family Care Hos' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Family Care Hos reported revenue of ₹0 Cr, +150.0% year on year, and net profit of −₹0 Cr.

### What is the shareholding pattern of Family Care Hos?

As of 30 Jun 2026: promoters 17.47%, domestic institutions 0.09%, non-institutions 82.44%. 65.47% of promoter shares were pledged.

### Who are Family Care Hos' competitors?

The listed Pharma & Healthcare companies closest to Family Care Hos by market cap are Vanta Bioscienc, Venmax Drugs, Zenith Health, Colinz Labs, Starsource Mult and Norris Medicine.

### Is Family Care Hos a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Family Care Hos' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FAMILYCARE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.